Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
Condition: Myelodysplastic Syndromes Interventions: Drug: Canakinumab Injection; Drug: Darbepoetin Alfa Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Novartis Pharmaceuticals Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials